Zydus Licenses Takeda's GERD Drug Vonoprazan for India
By Rediff Money Desk, New Delhi Jul 17, 2024 17:59
Zydus Lifesciences has signed a licensing deal with Takeda to market Vonoprazan, a P-CAB drug for GERD, in India under the brand name Vault.
![Zydus Licenses Takeda's GERD Drug Vonoprazan for India](https://im.rediff.com/money/2023/mar/31zydus.jpg)
Photograph: Courtesy Zydus.
New Delhi, Jul 17 (PTI) Zydus Lifesciences on Wednesday said it has inked a licensing pact with Takeda to market a drug for the treatment of gastroesophageal reflux disease (GERD).
The company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, the drug firm said in a statement.
The drug will be marketed under the brand name Vault in the country, it added.
Under the terms of this agreement, Zydus will be marketing the drug in India.
"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum," Zydus Lifesciences MD Sharvil Patel said.
Vonoprazan is approved by the DCGI (Drugs Controller General of India) for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD).
The company has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India, the drug firm said in a statement.
The drug will be marketed under the brand name Vault in the country, it added.
Under the terms of this agreement, Zydus will be marketing the drug in India.
"With a rich legacy in marketing gastrointestinal therapies in India, we have been offering different breakthrough clinical options across the spectrum," Zydus Lifesciences MD Sharvil Patel said.
Vonoprazan is approved by the DCGI (Drugs Controller General of India) for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD).
Source: PTI
Read More On:
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- GTL Infrastructure
- 2.93 ( -4.87)
- 226206286
- IFL Enterprises
- 1.30 (+ 4.84)
- 81461564
- Vodafone Idea L
- 16.79 (+ 0.66)
- 67447398
- NCL Research
- 0.95 ( -4.04)
- 31996628
- Franklin Industries
- 3.73 (+ 3.32)
- 21511209
MORE NEWS
Hathway Q1 Profit Down 18% to Rs 18.3 Cr,...
Hathway Cable & Datacom Ltd reported a decline of 18.1% in consolidated net...
![Vi Expands...](https://im.rediff.com/80-80/money/2021/feb/09spectrum.jpg)
Vi Expands Network Infrastructure in Kolkata...
Vodafone Idea (Vi) expands network infrastructure in Kolkata with new technology,...
![Real Estate PE...](https://im.rediff.com/80-80/money/2018/aug/30dollar.jpg)
Real Estate PE Investment Up 15% in H1 2024:...
Private equity investments in Indian real estate reached USD 3 billion in H1 2024,...